https://mindmedicinelaw.com/briefing/charlotte-integrates-ketamine-in-mental-health-treatment-20260706-19635The Psychedelic Journalen2026-07-06T22:04:39.965669+00:00Charlotte Integrates Ketamine in Mental Health Treatmentketamine treatment, mental health care, psychedelic therapies, depression treatment, PTSD therapy, Charlotte North Carolina, clinical trials, policy implications, patient access, treatment riskshttps://mindmedicinelaw.com/briefing/7-hydroxymitragynine-faces-schedule-i-proposal-in-u-s-20260706-19396The Psychedelic Journalen2026-07-06T15:05:37.017800+00:007-Hydroxymitragynine Faces Schedule I Proposal in U.S.7-hydroxymitragynine, Schedule I, kratom, Controlled Substances Act, public comments, OASH, drug policy, research restrictions, plant medicine, U.S. regulationhttps://mindmedicinelaw.com/briefing/subcutaneous-ketamine-for-depression-efficacy-and-safety-insights-20260706-19466The Psychedelic Journalen2026-07-06T15:05:25.122874+00:00Subcutaneous Ketamine for Depression: Efficacy and Safety Insightssubcutaneous ketamine, treatment-resistant depression, ketamine safety, ketamine efficacy, clinical trials, mental health treatment, depression therapies, psychiatric research, NMDA receptor antagonisthttps://mindmedicinelaw.com/briefing/oregon-s-proposed-psilocybin-fee-increases-impacts-and-implications-20260706-19476The Psychedelic Journalen2026-07-06T15:05:14.639147+00:00Oregon's Proposed Psilocybin Fee Increases: Impacts and Implicationsoregon psilocybin fees, psilocybin regulation, psychedelic industry, oregon policy changes, psilocybin business impact, therapeutic psilocybin, psilocybin market dynamics, regulatory framework, psilocybin legalization, psychedelic therapyhttps://mindmedicinelaw.com/briefing/dea-s-temporary-scheduling-of-mitragynine-derivatives-implications-20260706-19391The Psychedelic Journalen2026-07-06T15:05:02.263164+00:00DEA's Temporary Scheduling of Mitragynine Derivatives: ImplicationsDEA, mitragynine derivatives, Schedule I, psychedelic research, regulatory compliance, controlled substances, market impact, legal risks, research challenges, substance schedulinghttps://mindmedicinelaw.com/briefing/dea-moves-to-schedule-7-hydroxymitragynine-as-schedule-i-20260706-19392The Psychedelic Journalen2026-07-06T15:04:52.556079+00:00DEA Moves to Schedule 7-Hydroxymitragynine as Schedule IDEA, 7-hydroxymitragynine, Schedule I, controlled substances, psychedelic research, botanical industry, regulatory controls, substance abuse, research implications, market disruptionhttps://mindmedicinelaw.com/briefing/psilocybin-s-clinical-potential-and-legal-reevaluation-20260705-19521The Psychedelic Journalen2026-07-06T22:04:49.878841+00:00Psilocybin's Clinical Potential and Legal Reevaluationpsilocybin, psilocybe mushrooms, depression treatment, psychiatric disorders, serotonergic agonist, mental health protocols, schedule I drug, therapeutic potential, legal status, clinical trialshttps://mindmedicinelaw.com/briefing/trump-s-endorsement-of-psychedelic-therapy-policy-implications-20260705-19477The Psychedelic Journalen2026-07-06T15:05:49.731566+00:00Trump's Endorsement of Psychedelic Therapy: Policy Implicationspsychedelic therapy, Trump endorsement, federal policy, research funding, bipartisan support, mental health treatment, FDA breakthrough therapy, clinical trials, political polarization, ethical concernshttps://mindmedicinelaw.com/briefing/integrating-gender-affirming-care-in-ed-treatment-for-trans-people-20260704-19557The Psychedelic Journalen2026-07-06T22:05:09.443843+00:00Integrating Gender-Affirming Care in ED Treatment for Trans Peopleeating disorders, transgender health, gender-affirming care, mental health disparities, systematic review, clinical practice, policy implications, minority stressors, gender dysphoria, healthcare equityhttps://mindmedicinelaw.com/briefing/psychedelic-therapy-for-ibs-emerging-research-and-implications-20260704-19558The Psychedelic Journalen2026-07-06T22:05:00.121560+00:00Psychedelic Therapy for IBS: Emerging Research and Implicationsbrain-gut axis, irritable bowel syndrome, psychedelic-assisted therapy, personalized medicine, clinical trials, neurosciencehttps://mindmedicinelaw.com/briefing/oxytocin-and-mindfulness-therapy-a-new-approach-for-ssd-20260704-19541The Psychedelic Journalen2026-07-06T22:04:20.925207+00:00Oxytocin and Mindfulness Therapy: A New Approach for SSDoxytocin, mindfulness-based group therapy, schizophrenia spectrum disorders, negative symptoms, clinical trials, mental health treatmenthttps://mindmedicinelaw.com/briefing/drug-policy-and-human-optimization-a-regulatory-paradox-20260704-19152The Psychedelic Journalen2026-07-05T15:06:27.370956+00:00Drug Policy and Human Optimization: A Regulatory Paradoxdrug policy, psychoactive plants, human optimization, regulatory inconsistencies, liberty and harm, cultural influence, medical gatekeeping, legal status, adult autonomy, substance regulationhttps://mindmedicinelaw.com/briefing/ketamine-s-neural-mechanisms-in-treatment-resistant-depression-20260704-19163The Psychedelic Journalen2026-07-05T15:05:54.039652+00:00Ketamine's Neural Mechanisms in Treatment-Resistant Depressionketamine, treatment-resistant depression, high-order interactions, neural mechanisms, clinical outcomes, brain activity patterns, veterans, EEG, alpha-band, personalized treatmenthttps://mindmedicinelaw.com/briefing/mitochondrial-inflammation-link-in-mdd-psychedelic-potential-20260703-19121The Psychedelic Journalen2026-07-05T22:05:43.496466+00:00Mitochondrial-Inflammation Link in MDD: Psychedelic Potentialmitochondrial dysfunction, inflammation, major depressive disorder, psychedelic compounds, antidepressant strategies, clinical trials, mitochondrial pathways, neuroinflammation, FDA regulations, psychedelic researchhttps://mindmedicinelaw.com/briefing/excitation-inhibition-imbalance-in-sgacc-implications-for-depression-in-dlb-20260703-19166The Psychedelic Journalen2026-07-05T22:05:32.049906+00:00Excitation-Inhibition Imbalance in sgACC: Implications for Depression in DLBsgACC, dementia with Lewy bodies, depression, neurotransmission, glutamatergic, GABAergic, antidepressants, neurochemical changes, psychiatric treatment, synaptic changeshttps://mindmedicinelaw.com/briefing/predictive-processing-in-psychiatry-challenges-and-implications-20260703-19171The Psychedelic Journalen2026-07-05T22:05:23.704413+00:00Predictive Processing in Psychiatry: Challenges and Implicationspredictive processing, psychiatry, mental illness, psychedelic therapies, cultural variability, normative assumptions, PTSD, depression, autism, ADHDhttps://mindmedicinelaw.com/briefing/mystical-experiences-in-ketamine-therapy-insights-and-implications-20260703-19120The Psychedelic Journalen2026-07-05T22:05:13.573416+00:00Mystical Experiences in Ketamine Therapy: Insights and Implicationsketamine-assisted psychotherapy, mystical experiences, psychedelic therapy, anxiety treatment, migraine therapy, subjective experiences, psychological integration, therapeutic outcomes, Hood Mysticism Scale, Outcome Questionnaire-45https://mindmedicinelaw.com/briefing/nondual-meditation-alters-brain-connectome-in-experts-20260703-19155The Psychedelic Journalen2026-07-05T22:05:05.494687+00:00Nondual Meditation Alters Brain Connectome in Expertsnondual meditation, brain connectivity, consciousness research, self-representation, neural integration, mindfulness meditation, fMRI studies, altered states, neuroscience, expert meditatorshttps://mindmedicinelaw.com/briefing/neuroinflammation-s-role-in-depression-implications-for-treatment-20260703-19168The Psychedelic Journalen2026-07-05T15:06:35.942514+00:00Neuroinflammation's Role in Depression: Implications for Treatmentneuroinflammation, depression, immune-brain interface, treatment-resistant depression, biomarker stratification, psychiatry, antidepressants, glial activation, cytokines, precision medicinehttps://mindmedicinelaw.com/briefing/psilocybin-retreats-enhanced-by-targeted-therapy-study-finds-20260703-19118The Psychedelic Journalen2026-07-05T15:06:19.149828+00:00Psilocybin Retreats Enhanced by Targeted Therapy, Study Findspsilocybin retreats, psychotherapy interventions, ACT-PMNR, mental health outcomes, psychedelic therapy, observational study, randomized controlled trials, psychological integration, depression and anxiety, linear mixed model analysishttps://mindmedicinelaw.com/briefing/brain-gut-electrophysiology-in-predicting-antidepressant-response-20260703-19170The Psychedelic Journalen2026-07-05T15:06:11.165312+00:00Brain-Gut Electrophysiology in Predicting Antidepressant Responsebrain-gut electrophysiology, antidepressant response, depression subtypes, personalized treatment, biomarkers, clinical trials, mental health, electrophysiological markers, treatment prediction, clinical decision-makinghttps://mindmedicinelaw.com/briefing/esketamine-s-impact-on-post-op-depression-in-an-surgery-20260703-19165The Psychedelic Journalen2026-07-05T15:06:03.721653+00:00Esketamine's Impact on Post-Op Depression in AN Surgeryesketamine, postoperative depression, acoustic neuroma surgery, clinical trial, perioperative care, mental health outcomeshttps://mindmedicinelaw.com/briefing/comparative-efficacy-of-tf-cbt-and-emdr-in-ptsd-treatment-20260630-19138The Psychedelic Journalen2026-07-05T22:05:53.116370+00:00Comparative Efficacy of TF-CBT and EMDR in PTSD TreatmentPTSD treatment, TF-CBT, EMDR, trauma-focused therapy, clinical guidelines, psychotherapy efficacy, mental health, post-traumatic stress disorderhttps://mindmedicinelaw.com/briefing/psychedelics-and-autism-mechanisms-and-ethical-challenges-20260623-19626The Psychedelic Journalen2026-07-06T22:04:31.051227+00:00Psychedelics and Autism: Mechanisms and Ethical Challengespsychedelics, autism spectrum disorder, clinical trials, neuroscience, ethical challenges, serotonin receptors, neuroplasticity, informed consent, translational evidence, treatment protocols